Pulmonary Arterial Hypertension Associated with Interferon-beta Treatment for Multiple Sclerosis. Case Report and Literature Review

Overview

Journal Mult Scler Relat Disord

Specialty Neurology

Date 2019 Jan 15

PMID 30639829

Citations 5

Authors

Eftychia Demerouti

Panagiotis Karyofyllis

George Athanassopoulos

George Karatasakis

Dimitrios Tsiapras

Athanassios Manginas

Vasilios Voudris

Affiliations

Soon will be listed here.

Abstract

Drug-Induced Pulmonary Arterial Hypertension (PAH) represents a well-known entity, predominantly related to anorexigens. Interferon-β (IFN) is considered to be a drug with a possible risk of inducing PAH. We report a patient with Multiple Sclerosis treated with IFN-β who diagnosed with PAH and her course of disease under specific PAH drug therapy. A review of the literature in IFN-β-induced PAH is provided.

Citing Articles

Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension.

Hudson J, Farkas L Int J Mol Sci. 2021; 22(22).

PMID: 34829978 PMC: 8617605. DOI: 10.3390/ijms222212098.

Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.

Atabati E, Dehghani-Samani A, Mortazavimoghaddam S Can J Respir Ther. 2020; 56:1-9.

PMID: 33274259 PMC: 7690312. DOI: 10.29390/cjrt-2020-021.

Identification and Validation of Key Genes Associated With Systemic Sclerosis-Related Pulmonary Hypertension.

Zheng J, Li Y, Yan Y, Shi H, Zou T, Shao W Front Genet. 2020; 11:816.

PMID: 32793290 PMC: 7393672. DOI: 10.3389/fgene.2020.00816.

Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity.

Anthi A, Stagaki E, Rallidis L, Konstantonis D, Evangelopoulos M, Voumvourakis K ERJ Open Res. 2020; 6(1).

PMID: 32201683 PMC: 7073410. DOI: 10.1183/23120541.00328-2019.

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients.

Lerche M, Eichstaedt C, Hinderhofer K, Grunig E, Tausche K, Ziemssen T Pulm Circ. 2019; 9(3):2045894019872192.

PMID: 31798832 PMC: 6862775. DOI: 10.1177/2045894019872192.